• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

"Up the Price by How Much?"

Poll

Turing Pharmaceutical's CEO has backed down on the 4000% price hike for Daraprim, but is the damage done? Take our poll.

You’ve read about Turing Pharmaceuticals’ recent attempt to increase the cost of Daraprim by about 4000%.  

Do you think this move is:

A. Legitimate: funds will help subsidize new drug development
B. Motivated purely by financial gain and a harbinger of more to come
C. Not new: others have done it
D. A swan song: public and political pressure will stop this from becoming a trend
E. A priority issue for 2016 presidential candidates
F. Other
Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Lifestyle Intervention Shows Benefits Beyond Cognition in US POINTER Trial, Highlighting Modifiable Risk Factors for Dementia

Lifestyle Intervention Shows Benefits Beyond Cognition in US POINTER Trial, Highlighting Modifiable Risk Factors for Dementia

Grace Halsey
December 3rd 2025
Article

Two-year structured lifestyle "recipe" slowed cognitive aging and enhanced both cardiovascular and sleep health in older adults at risk for cognitive decline.

Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

Sydney Jennings
November 19th 2025
Podcast

Topics include new findings on oral acromegaly therapy, alcohol and dementia risk, tirzepatide in youth T2D, precision mood care, and LARC outcomes.

New Menopause Therapies Reflect a “Sea Change” in Women’s Health, Says Lisa Larkin, MD

New Menopause Therapies Reflect a “Sea Change” in Women’s Health, Says Lisa Larkin, MD

Sydney Jennings;Lisa Larkin, MD, FACP, MSCP, IF
December 2nd 2025
Article

Lisa Larkin, MD, explains how new therapies like elinzanetant reflect a major shift in menopause care and rising demand for better clinician education.

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Sydney Jennings
November 13th 2025
Podcast

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

Obesity Linked to Faster Alzheimer’s Disease Progression in Longitudinal Blood Biomarker Analysis / image credit Cyrus Raji, MD, PhD Courtesy of RSNA

Obesity Linked to Faster Alzheimer Disease Progression in Longitudinal Blood Biomarker Analysis

Grace Halsey
December 2nd 2025
Article

Biomarker trajectories over 5 years in study participants with AD show steeper rises in pTau217, NfL, and amyloid burden among those with obesity, highlighting risk factor relevance.

Anti-Tau Antibody Etalanetug Reduces Novel Tau Biomarker in Phase Ib/II Study

Anti-Tau Antibody Etalanetug Reduces Novel Tau Biomarker in Phase Ib/II Study

Sydney Jennings
December 2nd 2025
Article

New findings reveal etalanetug significantly reduces tau biomarkers in Alzheimer’s patients, paving the way for innovative blood-based assessments of tau pathology.

© 2025 MJH Life Sciences

All rights reserved.